The CAR T-cell therapy pipeline has experienced significant growth, with over 180 companies actively developing more than 200 innovative cell therapy candidates across various stages of clinical development.
Cartesian Therapeutics is set to begin a Phase 3 trial (AURORA) for Descartes-08, an mRNA CAR-T therapy, in patients with acetylcholine receptor autoantibody positive (AChR Ab+) myasthenia gravis (MG).